(Q33425869)

26 July 2017

title

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

adenocarcinoma

1 reference

pancreatic adenocarcinoma

inferred from title

1 reference

metastatic pancreatic adenocarcinoma

inferred from title

1 reference

19

Julien Taieb

1 reference

26 July 2017

David Tougeron

3

0 references

Jean-Baptiste Bachet

object named as

Jean-Baptiste Bachet

11

0 references

Pascal Hammel

object named as

Pascal Hammel

7

0 references

Romain Coriat

10

object named as

Romain Coriat

1 reference

26 July 2017

Alix Portal

1

1 reference

26 July 2017

Simon Pernot

2

1 reference

26 July 2017

Claire Arbaud

4

1 reference

26 July 2017

Anne Thirot Bidault

5

1 reference

26 July 2017

Christelle de la Fouchardière

6

1 reference

26 July 2017

Thierry Lecomte

8

1 reference

26 July 2017

Johann Dréanic

9

1 reference

26 July 2017

Olivier Dubreuil

12

1 reference

26 July 2017

Lysiane Marthey

13

1 reference

26 July 2017

Laetitia Dahan

14

1 reference

26 July 2017

Belinda Tchoundjeu

15

1 reference

26 July 2017

Christophe Locher

16

1 reference

26 July 2017

Céline Lepère

17

1 reference

26 July 2017

Franck Bonnetain

18

1 reference

26 July 2017

language of work or name

English

0 references

publication date

15 September 2015

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

113

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

989-995

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

26 July 2017

copyright license

start time

1 September 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

21 June 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651133

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.328

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.328

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.328

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.328

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.328

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26372701

12 December 2020

inferred from PubMed ID database lookup

Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26372701

12 December 2020

inferred from PubMed ID database lookup

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26372701

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/BJC.2015.328

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference